MarketResearchNest.com adds “Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2017” new report to its research database. The report spread across 417 pages with table and figures in it.
Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2017
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2017, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape.
Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient’s body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.
Browse full table of contents and data tables at
The Graft Versus Host Disease (GVHD) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 23, 9, 44, 9 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 2 molecules, respectively.
Graft Versus Host Disease (GVHD) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies Involved in Therapeutics Development
AbbVie Inc, AbGenomics International Inc, Allergan Plc, Amunix Operating Inc, AnaptysBio Inc, apceth Biopharma GmbH, Aptevo Therapeutics Inc, arGEN-X BV, Athersys Inc, Bellicum Pharmaceuticals Inc,
Bio-Cancer Treatment International Ltd, Biogen Inc, Bristol-Myers Squibb Company, Capricor Therapeutics Inc, Cell2B Advanced Therapeutics SA, Cellect Biomed Ltd, Commence Bio Inc, Cynata Therapeutics Ltd, Cytodyn Inc, Escape Therapeutics Inc, F. Hoffmann-La Roche Ltd, Fate Therapeutics Inc, Generon (Shanghai) Corp Ltd, Gilead Sciences Inc, GlaxoSmithKline Plc, Incyte Corp, Jazz Pharmaceuticals Plc, Johnson & Johnson, Kadmon Corp LLC, Kamada Ltd, Kiadis Pharma NV, Kymab Ltd,
Kyorin Pharmaceutical Co Ltd, MacroGenics Inc, Mallinckrodt Plc, Mesoblast Ltd, Millennium Pharmaceuticals Inc, Nohla Therapeutics Inc, Novartis AG, OncoImmune Inc, Pfizer Inc, Pharmicell Co Ltd, REGiMMUNE Corp, Sanofi, Sarepta Therapeutics Inc, Seattle Genetics Inc, Seres Therapeutics Inc,
Sigmoid Pharma Ltd, Synedgen Inc, Takeda Pharmaceutical Company Ltd, Targazyme Inc, TC BioPharm Ltd, TxCell SA, United BioPharma Inc, Vault Pharma Inc, VBI Vaccines Inc, Xenikos BV, XL-protein GmbH,
ZIOPHARM Oncology Inc.
Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=262572
– The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD) (Immunology).
– The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, RandD brief, MoA and other developmental activities.
– The pipeline guide reviews key companies involved in Graft Versus Host Disease (GVHD) (Immunology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Graft Versus Host Disease (GVHD) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) (Immunology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Request a sample copy at
MarketResearchNest.com is the most comprehensive collection of market research products and service Graft Versus Host Disease (GVHD) on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain